View DividendKBG マネジメントマネジメント 基準チェック /04現在、CEO に関する十分な情報がありません。主要情報Samuel Boo最高経営責任者n/a報酬総額CEO給与比率n/aCEO在任期間3.2yrsCEOの所有権n/a経営陣の平均在職期間データなし取締役会の平均在任期間データなし経営陣の近況お知らせ • Mar 13KBG Corp., Annual General Meeting, Mar 30, 2026KBG Corp., Annual General Meeting, Mar 30, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, goesan-gun, chungcheongbuk-do, South Koreaお知らせ • Feb 22KBG Corp., Annual General Meeting, Mar 24, 2025KBG Corp., Annual General Meeting, Mar 24, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, sari-myeon, goesan-gun, chungcheongbuk-do, South Koreaお知らせ • Feb 25Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021, at 10:00 Korea Standard Time.すべての更新を表示Recent updatesお知らせ • Mar 13KBG Corp., Annual General Meeting, Mar 30, 2026KBG Corp., Annual General Meeting, Mar 30, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, goesan-gun, chungcheongbuk-do, South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 10 April 2026. Trailing yield: 1.7%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.3%).分析記事 • Nov 20KBG's (KOSDAQ:318000) Soft Earnings Don't Show The Whole PictureInvestors were disappointed with the weak earnings posted by KBG Corp. ( KOSDAQ:318000 ). However, our analysis...Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: ₩45.00 (vs ₩60.00 in 3Q 2024)Third quarter 2025 results: EPS: ₩45.00 (down from ₩60.00 in 3Q 2024). Revenue: ₩4.71b (down 24% from 3Q 2024). Net income: ₩391.8m (down 25% from 3Q 2024). Profit margin: 8.3% (down from 8.4% in 3Q 2024). The decrease in margin was driven by lower revenue.お知らせ • Nov 07KBG Corp. announces Annual dividend, payable on April 10, 2026KBG Corp. announced Annual dividend of KRW 75.0000 per share payable on April 10, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.Reported Earnings • May 18First quarter 2025 earnings released: EPS: ₩57.00 (vs ₩95.49 in 1Q 2024)First quarter 2025 results: EPS: ₩57.00 (down from ₩95.49 in 1Q 2024). Revenue: ₩6.09b (up 27% from 1Q 2024). Net income: ₩493.4m (down 41% from 1Q 2024). Profit margin: 8.1% (down from 17% in 1Q 2024). The decrease in margin was driven by higher expenses.お知らせ • Feb 22KBG Corp., Annual General Meeting, Mar 24, 2025KBG Corp., Annual General Meeting, Mar 24, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, sari-myeon, goesan-gun, chungcheongbuk-do, South KoreaNew Risk • Feb 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (₩42.0b market cap, or US$29.2m).Buy Or Sell Opportunity • Jan 06Now 20% overvaluedOver the last 90 days, the stock has fallen 23% to ₩4,835. The fair value is estimated to be ₩4,029, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years, while earnings per share has been flat.Upcoming Dividend • Dec 20Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.9%). In line with average of industry peers (2.2%).New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩41.5b market cap, or US$28.9m).Valuation Update With 7 Day Price Move • Dec 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩3,890, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 9x in the Chemicals industry in South Korea. Total loss to shareholders of 52% over the past three years.分析記事 • Dec 06Earnings Working Against KBG Corp.'s (KOSDAQ:318000) Share Price Following 26% DiveTo the annoyance of some shareholders, KBG Corp. ( KOSDAQ:318000 ) shares are down a considerable 26% in the last...Buy Or Sell Opportunity • Nov 18Now 23% overvaluedOver the last 90 days, the stock has fallen 25% to ₩4,930. The fair value is estimated to be ₩4,000, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years, while earnings per share has been flat.Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩6,040, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total loss to shareholders of 30% over the past three years.New Risk • Aug 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩67.7b market cap, or US$50.7m).Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improves as stock rises 32%After last week's 32% share price gain to ₩7,750, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 4.7% over the past three years.分析記事 • Aug 06The Market Doesn't Like What It Sees From KBG Corp.'s (KOSDAQ:318000) Earnings Yet As Shares Tumble 29%KBG Corp. ( KOSDAQ:318000 ) shareholders that were waiting for something to happen have been dealt a blow with a 29...Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩4,900, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 44% over the past three years.分析記事 • May 21We Think That There Are Some Issues For KBG (KOSDAQ:318000) Beyond Its Promising EarningsKBG Corp.'s ( KOSDAQ:318000 ) healthy profit numbers didn't contain any surprises for investors. However the statutory...Upcoming Dividend • Dec 20Inaugural dividend of ₩99.50 per shareEligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. This is the first dividend for KBG since going public. The average dividend yield among industry peers is 1.8%.New Risk • Oct 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Shareholders have been diluted in the past year (5.7% increase in shares outstanding). Market cap is less than US$100m (₩83.9b market cap, or US$62.0m).Valuation Update With 7 Day Price Move • Oct 23Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩9,600, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 46% over the past three years.Valuation Update With 7 Day Price Move • Aug 17Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₩11,370, the stock trades at a trailing P/E ratio of 33.4x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 38% over the past three years.Valuation Update With 7 Day Price Move • Jul 27Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩8,900, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 31% over the past three years.New Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Shareholders have been diluted in the past year (5.7% increase in shares outstanding). Market cap is less than US$100m (₩115.7b market cap, or US$89.6m).Valuation Update With 7 Day Price Move • May 23Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩14,340, the stock trades at a trailing P/E ratio of 39.9x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 117% over the past three years.Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩16,260, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 213% over the past three years.Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 57%After last week's 57% share price gain to ₩16,830, the stock trades at a trailing P/E ratio of 42.8x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 220% over the past three years.Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩11,700, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 137% over the past three years.Valuation Update With 7 Day Price Move • Mar 07Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩9,650, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 76% over the past three years.Upcoming Dividend • Dec 21Inaugural dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. This is the first dividend for KBG since going public. The average dividend yield among industry peers is 2.4%.Reported Earnings • Nov 17Third quarter 2022 earnings released: EPS: ₩169 (vs ₩117 in 3Q 2021)Third quarter 2022 results: EPS: ₩169 (up from ₩117 in 3Q 2021). Revenue: ₩6.29b (down 9.1% from 3Q 2021). Net income: ₩1.39b (up 45% from 3Q 2021). Profit margin: 22% (up from 14% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩6,130, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 23% over the past three years.Valuation Update With 7 Day Price Move • Sep 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩4,855, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 36% over the past three years.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩6,280, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total loss to shareholders of 27% over the past year.Upcoming Dividend • Dec 22Inaugural dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Korea Bio-GenLtd since going public. The average dividend yield among industry peers is 1.4%.Reported Earnings • Nov 16Third quarter 2021 earnings released: EPS ₩117 (vs ₩121 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₩6.91b (up 25% from 3Q 2020). Net income: ₩954.3m (down 2.2% from 3Q 2020). Profit margin: 14% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩10,600, the stock trades at a trailing P/E ratio of 21.4x. Average trailing P/E is 19x in the Chemicals industry in South Korea. Total returns to shareholders of 34% over the past year.お知らせ • May 13Korea Bio-Gen Co.,Ltd announced that it has received KRW 5 billion in funding from Daegyeong Investment Co., Ltd. and another investorOn May 12, 2021, Korea Bio-Gen Co.,Ltd (KOSDAQ:A318000) closed the transaction.お知らせ • May 11Korea Bio-Gen Co.,Ltd announced that it expects to receive KRW 5 billion in funding from Daegyeong Investment Co., Ltd. and another investorKorea Bio-Gen Co., Ltd. (KOSDAQ:A318000) announced that it will issue series 3 unregistered coupon nonguaranteed private convertible bond for gross proceeds of KRW 5,000,000,000 on May 10, 2021. The transaction will include participation from Core Mezzanine PJT Hedge Fund 2 for KRW 3,000,000,000 and existing investor Daegyeong Investment Co., Ltd. for KRW 2,000,000,000. The bonds does not bear any interest and matures on May 12, 2026. The bonds are convertible into 542,299 shares at a fixed conversion price of KRW 9,220 per share from May 12, 2022 to April 12, 2026. The expected subscription and payment date is May 12, 2021. The transaction is approved by the board of directors of the company.分析記事 • Mar 02If You Had Bought Korea Bio-GenLtd (KOSDAQ:318000) Stock A Year Ago, You Could Pocket A 33% Gain TodayOn average, over time, stock markets tend to rise higher. This makes investing attractive. But if when you choose to...お知らせ • Feb 25Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021, at 10:00 Korea Standard Time.分析記事 • Feb 03The Trends At Korea Bio-GenLtd (KOSDAQ:318000) That You Should Know AboutWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Valuation Update With 7 Day Price Move • Jan 21Investor sentiment improved over the past weekAfter last week's 29% share price gain to ₩10,950, the stock is trading at a trailing P/E ratio of 30.4x, up from the previous P/E ratio of 23.6x. This compares to an average P/E of 18x in the Chemicals industry in South Korea. Total returns to shareholders over the past year are 63%.Is New 90 Day High Low • Jan 21New 90-day high: ₩10,950The company is up 48% from its price of ₩7,390 on 23 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 39% over the same period.Is New 90 Day High Low • Jan 04New 90-day high: ₩8,390The company is up 2.0% from its price of ₩8,260 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period.分析記事 • Dec 29Should You Be Impressed By Korea Bio-Gen Co.,Ltd's (KOSDAQ:318000) ROE?While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...Upcoming Dividend • Dec 22First Dividend Is ₩50.00 Per ShareWill be paid on the 10th of April to those who are registered shareholders by the 29th of December. This is the first dividend for Korea Bio-GenLtd since going public. The average dividend yield among industry peers is 0.9%.分析記事 • Dec 02Calculating The Intrinsic Value Of Korea Bio-Gen Co.,Ltd (KOSDAQ:318000)How far off is Korea Bio-Gen Co.,Ltd ( KOSDAQ:318000 ) from its intrinsic value? Using the most recent financial data...Is New 90 Day High Low • Oct 26New 90-day low: ₩6,880The company is down 4.0% from its price of ₩7,160 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period.CEOSamuel Boo (39 yo)3.2yrs在職期間Samuel Boo is Director of KBG Corp. and is its CEO since March 23, 2023.View Ownership企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 06:25終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋KBG Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 13KBG Corp., Annual General Meeting, Mar 30, 2026KBG Corp., Annual General Meeting, Mar 30, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, goesan-gun, chungcheongbuk-do, South Korea
お知らせ • Feb 22KBG Corp., Annual General Meeting, Mar 24, 2025KBG Corp., Annual General Meeting, Mar 24, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, sari-myeon, goesan-gun, chungcheongbuk-do, South Korea
お知らせ • Feb 25Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021, at 10:00 Korea Standard Time.
お知らせ • Mar 13KBG Corp., Annual General Meeting, Mar 30, 2026KBG Corp., Annual General Meeting, Mar 30, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, goesan-gun, chungcheongbuk-do, South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 10 April 2026. Trailing yield: 1.7%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.3%).
分析記事 • Nov 20KBG's (KOSDAQ:318000) Soft Earnings Don't Show The Whole PictureInvestors were disappointed with the weak earnings posted by KBG Corp. ( KOSDAQ:318000 ). However, our analysis...
Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: ₩45.00 (vs ₩60.00 in 3Q 2024)Third quarter 2025 results: EPS: ₩45.00 (down from ₩60.00 in 3Q 2024). Revenue: ₩4.71b (down 24% from 3Q 2024). Net income: ₩391.8m (down 25% from 3Q 2024). Profit margin: 8.3% (down from 8.4% in 3Q 2024). The decrease in margin was driven by lower revenue.
お知らせ • Nov 07KBG Corp. announces Annual dividend, payable on April 10, 2026KBG Corp. announced Annual dividend of KRW 75.0000 per share payable on April 10, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
Reported Earnings • May 18First quarter 2025 earnings released: EPS: ₩57.00 (vs ₩95.49 in 1Q 2024)First quarter 2025 results: EPS: ₩57.00 (down from ₩95.49 in 1Q 2024). Revenue: ₩6.09b (up 27% from 1Q 2024). Net income: ₩493.4m (down 41% from 1Q 2024). Profit margin: 8.1% (down from 17% in 1Q 2024). The decrease in margin was driven by higher expenses.
お知らせ • Feb 22KBG Corp., Annual General Meeting, Mar 24, 2025KBG Corp., Annual General Meeting, Mar 24, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, sari-myeon, goesan-gun, chungcheongbuk-do, South Korea
New Risk • Feb 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (₩42.0b market cap, or US$29.2m).
Buy Or Sell Opportunity • Jan 06Now 20% overvaluedOver the last 90 days, the stock has fallen 23% to ₩4,835. The fair value is estimated to be ₩4,029, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years, while earnings per share has been flat.
Upcoming Dividend • Dec 20Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.9%). In line with average of industry peers (2.2%).
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩41.5b market cap, or US$28.9m).
Valuation Update With 7 Day Price Move • Dec 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩3,890, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 9x in the Chemicals industry in South Korea. Total loss to shareholders of 52% over the past three years.
分析記事 • Dec 06Earnings Working Against KBG Corp.'s (KOSDAQ:318000) Share Price Following 26% DiveTo the annoyance of some shareholders, KBG Corp. ( KOSDAQ:318000 ) shares are down a considerable 26% in the last...
Buy Or Sell Opportunity • Nov 18Now 23% overvaluedOver the last 90 days, the stock has fallen 25% to ₩4,930. The fair value is estimated to be ₩4,000, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years, while earnings per share has been flat.
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩6,040, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total loss to shareholders of 30% over the past three years.
New Risk • Aug 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩67.7b market cap, or US$50.7m).
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improves as stock rises 32%After last week's 32% share price gain to ₩7,750, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 4.7% over the past three years.
分析記事 • Aug 06The Market Doesn't Like What It Sees From KBG Corp.'s (KOSDAQ:318000) Earnings Yet As Shares Tumble 29%KBG Corp. ( KOSDAQ:318000 ) shareholders that were waiting for something to happen have been dealt a blow with a 29...
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩4,900, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 44% over the past three years.
分析記事 • May 21We Think That There Are Some Issues For KBG (KOSDAQ:318000) Beyond Its Promising EarningsKBG Corp.'s ( KOSDAQ:318000 ) healthy profit numbers didn't contain any surprises for investors. However the statutory...
Upcoming Dividend • Dec 20Inaugural dividend of ₩99.50 per shareEligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. This is the first dividend for KBG since going public. The average dividend yield among industry peers is 1.8%.
New Risk • Oct 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Shareholders have been diluted in the past year (5.7% increase in shares outstanding). Market cap is less than US$100m (₩83.9b market cap, or US$62.0m).
Valuation Update With 7 Day Price Move • Oct 23Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩9,600, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 46% over the past three years.
Valuation Update With 7 Day Price Move • Aug 17Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₩11,370, the stock trades at a trailing P/E ratio of 33.4x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 38% over the past three years.
Valuation Update With 7 Day Price Move • Jul 27Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩8,900, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 31% over the past three years.
New Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Shareholders have been diluted in the past year (5.7% increase in shares outstanding). Market cap is less than US$100m (₩115.7b market cap, or US$89.6m).
Valuation Update With 7 Day Price Move • May 23Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩14,340, the stock trades at a trailing P/E ratio of 39.9x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 117% over the past three years.
Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩16,260, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 213% over the past three years.
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 57%After last week's 57% share price gain to ₩16,830, the stock trades at a trailing P/E ratio of 42.8x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 220% over the past three years.
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩11,700, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 137% over the past three years.
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩9,650, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 76% over the past three years.
Upcoming Dividend • Dec 21Inaugural dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. This is the first dividend for KBG since going public. The average dividend yield among industry peers is 2.4%.
Reported Earnings • Nov 17Third quarter 2022 earnings released: EPS: ₩169 (vs ₩117 in 3Q 2021)Third quarter 2022 results: EPS: ₩169 (up from ₩117 in 3Q 2021). Revenue: ₩6.29b (down 9.1% from 3Q 2021). Net income: ₩1.39b (up 45% from 3Q 2021). Profit margin: 22% (up from 14% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩6,130, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 23% over the past three years.
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩4,855, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 36% over the past three years.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩6,280, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total loss to shareholders of 27% over the past year.
Upcoming Dividend • Dec 22Inaugural dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Korea Bio-GenLtd since going public. The average dividend yield among industry peers is 1.4%.
Reported Earnings • Nov 16Third quarter 2021 earnings released: EPS ₩117 (vs ₩121 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₩6.91b (up 25% from 3Q 2020). Net income: ₩954.3m (down 2.2% from 3Q 2020). Profit margin: 14% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩10,600, the stock trades at a trailing P/E ratio of 21.4x. Average trailing P/E is 19x in the Chemicals industry in South Korea. Total returns to shareholders of 34% over the past year.
お知らせ • May 13Korea Bio-Gen Co.,Ltd announced that it has received KRW 5 billion in funding from Daegyeong Investment Co., Ltd. and another investorOn May 12, 2021, Korea Bio-Gen Co.,Ltd (KOSDAQ:A318000) closed the transaction.
お知らせ • May 11Korea Bio-Gen Co.,Ltd announced that it expects to receive KRW 5 billion in funding from Daegyeong Investment Co., Ltd. and another investorKorea Bio-Gen Co., Ltd. (KOSDAQ:A318000) announced that it will issue series 3 unregistered coupon nonguaranteed private convertible bond for gross proceeds of KRW 5,000,000,000 on May 10, 2021. The transaction will include participation from Core Mezzanine PJT Hedge Fund 2 for KRW 3,000,000,000 and existing investor Daegyeong Investment Co., Ltd. for KRW 2,000,000,000. The bonds does not bear any interest and matures on May 12, 2026. The bonds are convertible into 542,299 shares at a fixed conversion price of KRW 9,220 per share from May 12, 2022 to April 12, 2026. The expected subscription and payment date is May 12, 2021. The transaction is approved by the board of directors of the company.
分析記事 • Mar 02If You Had Bought Korea Bio-GenLtd (KOSDAQ:318000) Stock A Year Ago, You Could Pocket A 33% Gain TodayOn average, over time, stock markets tend to rise higher. This makes investing attractive. But if when you choose to...
お知らせ • Feb 25Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021, at 10:00 Korea Standard Time.
分析記事 • Feb 03The Trends At Korea Bio-GenLtd (KOSDAQ:318000) That You Should Know AboutWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
Valuation Update With 7 Day Price Move • Jan 21Investor sentiment improved over the past weekAfter last week's 29% share price gain to ₩10,950, the stock is trading at a trailing P/E ratio of 30.4x, up from the previous P/E ratio of 23.6x. This compares to an average P/E of 18x in the Chemicals industry in South Korea. Total returns to shareholders over the past year are 63%.
Is New 90 Day High Low • Jan 21New 90-day high: ₩10,950The company is up 48% from its price of ₩7,390 on 23 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 39% over the same period.
Is New 90 Day High Low • Jan 04New 90-day high: ₩8,390The company is up 2.0% from its price of ₩8,260 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period.
分析記事 • Dec 29Should You Be Impressed By Korea Bio-Gen Co.,Ltd's (KOSDAQ:318000) ROE?While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Upcoming Dividend • Dec 22First Dividend Is ₩50.00 Per ShareWill be paid on the 10th of April to those who are registered shareholders by the 29th of December. This is the first dividend for Korea Bio-GenLtd since going public. The average dividend yield among industry peers is 0.9%.
分析記事 • Dec 02Calculating The Intrinsic Value Of Korea Bio-Gen Co.,Ltd (KOSDAQ:318000)How far off is Korea Bio-Gen Co.,Ltd ( KOSDAQ:318000 ) from its intrinsic value? Using the most recent financial data...
Is New 90 Day High Low • Oct 26New 90-day low: ₩6,880The company is down 4.0% from its price of ₩7,160 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period.